McKesson Corporation $MCK Shares Sold by Union Bancaire Privee UBP SA

Union Bancaire Privee UBP SA lessened its holdings in McKesson Corporation (NYSE:MCK) by 29.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,308 shares of the company’s stock after selling 956 shares during the period. Union Bancaire Privee UBP SA’s holdings in McKesson were worth $1,859,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of MCK. J.W. Cole Advisors Inc. raised its position in McKesson by 35.3% during the third quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock worth $3,931,000 after acquiring an additional 1,329 shares during the period. Private Wealth Partners LLC grew its position in shares of McKesson by 5.6% in the third quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock valued at $24,598,000 after purchasing an additional 1,682 shares during the period. AlphaQuest LLC increased its stake in shares of McKesson by 91.2% during the third quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock worth $1,365,000 after purchasing an additional 843 shares in the last quarter. CW Advisors LLC raised its position in shares of McKesson by 282.5% during the 2nd quarter. CW Advisors LLC now owns 11,008 shares of the company’s stock worth $8,067,000 after purchasing an additional 8,130 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its stake in McKesson by 12.4% in the 3rd quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company’s stock valued at $255,438,000 after buying an additional 36,451 shares in the last quarter. Hedge funds and other institutional investors own 85.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on MCK shares. Morgan Stanley reiterated an “overweight” rating and issued a $966.00 price objective on shares of McKesson in a report on Thursday, January 29th. Weiss Ratings downgraded McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a research report on Thursday, February 5th. Robert W. Baird set a $968.00 price target on McKesson in a research note on Wednesday, January 14th. Wall Street Zen cut McKesson from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, Mizuho raised their price objective on McKesson from $880.00 to $885.00 and gave the company a “neutral” rating in a report on Thursday, February 5th. Thirteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $960.93.

McKesson Trading Down 1.2%

MCK stock opened at $888.28 on Friday. The company has a market cap of $108.80 billion, a price-to-earnings ratio of 25.55, a PEG ratio of 1.45 and a beta of 0.38. McKesson Corporation has a 12 month low of $637.00 and a 12 month high of $999.00. The firm has a 50-day moving average of $903.68 and a two-hundred day moving average of $832.51.

McKesson (NYSE:MCK) last issued its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, topping the consensus estimate of $9.19 by $0.15. The business had revenue of $106.16 billion for the quarter, compared to analysts’ expectations of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, equities analysts forecast that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be paid a $0.82 dividend. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. McKesson’s dividend payout ratio (DPR) is 9.43%.

Insider Buying and Selling at McKesson

In related news, EVP Thomas L. Rodgers sold 276 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $816.18, for a total value of $225,265.68. Following the completion of the sale, the executive vice president owned 2,268 shares of the company’s stock, valued at approximately $1,851,096.24. This represents a 10.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Leann B. Smith sold 190 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total transaction of $179,550.00. Following the sale, the executive vice president owned 2,989 shares of the company’s stock, valued at approximately $2,824,605. The trade was a 5.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 3,868 shares of company stock worth $3,743,820. Corporate insiders own 0.08% of the company’s stock.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.